Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2019

View Archived Issues

Decreased inhibition, but no hyperexcitation, in multiple autism models

The Model T of CAR T cells?

Novo Nordisk initiates phase II study of NNC-0174-0833 for weight management

Serum CIRP as novel biomarker for monitoring disease activity in alopecia areata

Exosome therapy for hair loss shows promise

Eli Lilly studies LY-3375880 in phase II trial for moderate to severe atopic dermatitis

BARDA supports development of vaccine against Marburg virus infection

PPT1 inhibition through DC-661 compound shows antitumoral effects

SpringWorks Therapeutics initiates phase III study of nirogacestat

In gut, skin fungus may contribute to IBD

Tyme Technologies adds preclinical candidate to pipeline

Novel noninvasive rodent model of alopecia areata described

New variant of genetic mutation in the ANTXR2 gene found to be associated with hyaline fibromatosis

CBT-509 demonstrates promising efficacy in preclinical cancer models

Pirfenidone partially reverses severe pulmonary arterial hypertension in rat models

Novel tumor microenvironment system based on a 3D human co-culture with patient-derived tumor cells

GlaxoSmithKline and BioVersys divulge new antimycobacterials

Idorsia Pharmaceuticals discloses IDO1 and/or TDO inhibitors

Roche discloses metabotropic glutamate mGlu4 receptor PAMs

Agios Pharmaceuticals patents PKLR activators

European approval for Tecentriq with Avastin and chemotherapy for metastatic non-squamous NSCLC

Pfizer identifies TYK2 inhibitors

HOXC6 gene expression linked to cervical cancer progression

Helsinn opens phase III program with anamorelin to treat weight loss and anorexia in NSCLC cachexia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...